High Purity 99% Ciprofloxacin Hydrochloride CAS 86483-48-9

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >98%
• Model NO.: TGY022019061703
• Product Name: Ciprofloxacin Hydrochloride
• Specificcation: 99%
• Grade: Medicine Grade
• Storage: Cool Dry Place
• Shipping Time: Within 3-7 Working Days
• Appearance: White Powder
• CAS No.: 86483-48-9
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• HS Code: 300440906
• Production Capacity: 1500kg/Month

Product Description

Product Name	Ciprofloxacin hydrochloride
Synonyms	Ciprofloxacin base HCL CAS 86483-48-9
CAS:	Ciprofloxacin hydrochloride 86483-48-9
MF:	-
MW:	-
EINECS:	-
Product Categories:	Agrochemical Intermediates;Intermediates & Fine Chemicals;Dyestuff Intermediates;Flavor & Fragrance Intermediates;Gatiflo, Tequin and Zymar;Pharmaceutical intermediates

_{Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-() rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."}
 

_{In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections.[4] In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis.}